The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
HER‐2‐Targeted Nanoparticle–Affibody Bioconjugates for Cancer Therapy
Open accessAbstract
Affibodies are a class of polypeptide ligand that are potential candidates for tissue-specific targeting of drug-encapsulated controlled release polymeric nanoparticles (NPs). We developed drug delivery vehicles composed of polymeric NPs surface modified with affibody ligands that bind the extracellular domain of the human epidermal growth factor receptor 2 (HER-2) for targeted delivery to cells that overexpress the HER-2 antigen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RGD AND OTHER RECOGNITION SEQUENCES FOR INTEGRINS
Ruoslahti, E. (1996) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.12.1.697 · Cited by 3,191
Formulation of functionalized PLGA-PEG Nanoparticles for in vivo targeted drug delivery
Cheng, J., Teply, B. A., Sherifi, I., Sung, J., Luther, G., Gu, F. X., Levy-Nissenbaum, E., Radovic-Moreno, A. F., Langer, R., & Farokhzad, O. C. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.09.047 · Cited by 1,273
Self-citationLee, K. S., Chung, H. C., Im, S. A., Park, Y. H., Kim, C. S., Kim, S.-B., Rha, S. Y., Lee, M. Y., & Ro, J. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9591-y · Cited by 541
Biodegradable, polymeric nanoparticle delivery systems for cancer therapy
Pridgen, E. M., Langer, R., & Farokhzad, O. C. (2007) · Nanomedicine · doi:10.2217/17435889.2.5.669 · Cited by 249
Self-citation
Cited by
Cellular uptake of nanoparticles: Journey inside the cell
Behzadi, S., Serpooshan, V., Tao, W., Hamaly, M. A., Alkawareek, M. Y., Dreaden, E. C., Brown, D., Alkilany, A. M., Farokhzad, O. C., & Mahmoudi, M. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00636a · Cited by 2,859
Self-citationBertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Self-citationTargeted polymeric therapeutic nanoparticles: design, development and clinical translation
Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F., & Farokhzad, O. C. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15344k · Cited by 1,730
Self-citationNanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance
Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., Wu, S., Deng, Y., Zhang, J., & Shao, A. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00193 · Cited by 1,451
Nicolas, J., Mura, S., Brambilla, D., Mackiewicz, N., & Couvreur, P. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35265f · Cited by 1,270
Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to Clinic
Puri, A., Loomis, K., Smith, B., Lee, J.-H., Yavlovich, A., Heldman, E., & Blumenthal, R. (2009) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v26.i6.10 · Cited by 1,069
Löfblom, J., Feldwisch, J., Tolmachev, V., Carlsson, J., Ståhl, S., & Frejd, F. Y. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.04.014 · Cited by 651
Applications of novel drug delivery system for herbal formulations
Ajazuddin, & Saraf, S. (2010) · Fitoterapia · doi:10.1016/j.fitote.2010.05.001 · Cited by 624
The role of HER2 in cancer therapy and targeted drug delivery
Tai, W., Mahato, R., & Cheng, K. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.04.009 · Cited by 555
Bioavailability of phytochemicals and its enhancement by drug delivery systems
Aqil, F., Munagala, R., Jeyabalan, J., & Vadhanam, M. V. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.02.032 · Cited by 398
Nucleic Acid and Peptide Aptamers: Fundamentals and Bioanalytical Aspects
Mascini, M., Palchetti, I., & Tombelli, S. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201006630 · Cited by 374
Gold nanoparticles: Emerging paradigm for targeted drug delivery system
Kumar, A., Zhang, X., & Liang, X.-J. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2012.10.002 · Cited by 371
Nanoparticle Technologies for Cancer Therapy
Alexis, F., Pridgen, E. M., Langer, R., & Farokhzad, O. C. (2010) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-00477-3_2 · Cited by 364
Self-citationNanotechnology-based approaches in anticancer research
Kamal, M. A., Jabir NR, N., Tabrez, Ashraf, Shakil, & Damanhouri (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s33838 · Cited by 363
Iron oxide nanoparticles for targeted cancer imaging and diagnostics
Rosen, J. E., Chan, L., Shieh, D.-B., & Gu, F. X. (2012) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2011.08.017 · Cited by 329
Ultrasmall inorganic nanoparticles: State-of-the-art and perspectives for biomedical applications
Zarschler, K., Rocks, L., Licciardello, N., Boselli, L., Polo, E., Garcia, K. P., De Cola, L., Stephan, H., & Dawson, K. A. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2016.02.019 · Cited by 303
Metadata
- Authors
- Alexis, F., Basto, P., Levy‐Nissenbaum, E., Radovic‐Moreno, A. F., Zhang, L., Pridgen, E., Wang, A. Z., Marein, S. L., Westerhof, K., Molnar, L. K., & Farokhzad, O. C.
- Venue
- ChemMedChem
- Publisher
- Wiley
- Published
- 2008-12-08
- Volume
- 3
- Issue
- 12
- Pages
- 1839-1843
- ISSN
- 1860-7179 (ISSN-L)
- 1860-7187
- OpenAlex
- W2029335572
- Cited by
- 164
- References
- 4
- FWCI
- 4.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.